Document:

Exhibit 4.1

 

SECOND AMENDMENT

 

TO

 

SHAREHOLDER RIGHTS PLAN

 

This Second Amendment (the “Second Amendment”)
to the Shareholder Rights Plan (the “Plan”) of St. Mary Land & Exploration
Company, a Delaware corporation (the “Company”), is executed effective as of
April 24, 2006.

 

RECITALS

 

WHEREAS, the Plan was established effective
as of August 1, 1999 and was previously amended by a First Amendment to the
Plan effective as of July 19, 2001;

 

WHEREAS, the Board of Directors of the
Company has determined that it is in the best interests of the Company’s
stockholders to further amend the Plan as set forth in this Second Amendment;
and

 

WHEREAS, capitalized terms used but not
defined in this Second Amendment shall have the meanings previously given to
them in the Plan.

 

NOW, THEREFORE, the
Plan is hereby amended as follows:

 

AMENDMENT

 

1.             Section 1(k) of the Plan is hereby
amended in its entirety to read as follows:

 

“Final Expiration Date” shall mean December
31, 2011.

 

2.             Section 1(r) of the Plan is hereby
amended in its entirety to read as follows:

 

“Purchase Price” shall mean, from and after
April 24, 2006, $140.00 per share of Common Stock and shall be subject to
adjustment thereafter from time to time as provided in this Plan.

 

3.             The first sentence of Section 3(a)
of the Plan is hereby amended in its entirety to read as follows:

 

At any time after the Distribution Date and
prior to the Expiration Date, the registered holder of any Right may exercise
such Right by written notice to the Company of such exercise together with
payment of the Purchase Price for the Common Share as to which such Right is
exercised.

 

The remainder of the Plan shall be unaffected
by this Second Amendment.

 

 

IN WITNESS WHEREOF, the Company has caused
this Second Amendment to the Shareholder Rights Plan to be duly executed on its
behalf on April 24, 2006.

 

	
   

  	
  ST. MARY
  LAND & EXPLORATION COMPANY,

  
	
   

  	
  a Delaware
  corporation

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /S/ MARK A. HELLERSTEIN

  	
   

  
	
   

  	
   

  	
  Mark A.
  Hellerstein

  
	
   

  	
   

  	
  Chairman of
  the Board, President and

  
	
   

  	
   

  	
  Chief
  Executive OfficerExhibit 10.1

 

EXECUTION COPY

 

AMENDMENT NO. 3

TO

TRANSACTION AGREEMENT

 

THIS AMENDMENT NO. 3 TO TRANSACTION AGREEMENT
(this “Amendment 3”), dated as of February 22, 2006, between BOSTON
SCIENTIFIC CORPORATION, a Delaware corporation (“Boston Scientific”), and
ABBOTT LABORATORIES, an Illinois corporation (“Abbott”).

 

WHEREAS,
Boston Scientific and Abbott are parties to that certain Transaction Agreement
dated as of January 8, 2006 and amended by Amendment Nos. 1 and 2 thereto
dated as of January 16, 2006, pursuant to which Abbott agreed to acquire
certain assets and businesses and assume certain liabilities of Guidant
contingent upon Boston Scientific’s acquisition of Guidant (the “Agreement”);
and

 

WHEREAS,
Boston Scientific and Abbott desire to further amend the Agreement as provided
in this Amendment 3 in accordance with Section 12.07 of the Agreement.

 

NOW, THEREFORE, in consideration of the
foregoing and the promises and mutual agreements contained in this Amendment 3,
and for other good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, and intending to be legally bound, the parties
hereto agree as follows:

 

SECTION 1. Amendments to the
Agreement. (a) Section 2.03(b) of the Agreement is hereby
amended and restated to read as follows:

 

“(b)                           On or
before March 1, 2006, Abbott shall provide Boston Scientific with a
proposed allocation of the Purchase Price among the Asset categories (the “Allocation”)
for Boston Scientific’s review and comment. For purposes of the Allocation,
Asset categories shall consist of the following two classes:  (i) Assets located or owned in the
United States, and (ii) Assets located or owned outside of the United
States. If Boston Scientific does not provide any comments to Abbott in writing
within 17 days following delivery by Abbott of the proposed Allocation, then
the Allocation proposed by Abbott shall be deemed to be final and binding,
absent manifest error. If, however, Boston Scientific submits comments to
Abbott within such 17-day period, Abbott and Boston Scientific shall negotiate
in good faith to resolve any differences within 12 days of such submission. If
Boston Scientific and Abbott are unable to reach a resolution within such 12
day period, then all remaining disputed items shall be submitted for resolution
by an internationally-recognized, independent accounting firm mutually selected
by Abbott and Boston Scientific (the “Allocation Accounting Firm”),
which shall make a final determination as to the disputed items within 17 days
after such submission, but in no event later than 20 days following the closing
of the Merger, and such determination shall be final and binding on Boston
Scientific and

 

 

Abbott. The fees and disbursements of the
Allocation Accounting Firm shall be shared equally between Boston Scientific
and Abbott. Any subsequent adjustments to the Purchase Price shall be reflected
in the Allocation in a manner consistent with Section 1060 of the Code and
the Regulations thereunder. For all Tax purposes, Abbott and Boston Scientific
agree that the transactions contemplated by this Agreement shall be reported in
a manner consistent with the terms of this Agreement, including the Allocation,
and that neither of them will take any position inconsistent therewith in any
Tax Return, in any refund claim, in any litigation, or otherwise.”

 

(b)                                 Section 5.07(b) of
the Agreement is hereby amended and restated to read as follows:

 

“(b)                           (i) 
During the term of the supply arrangements, if Boston Scientific manufactures
drug eluting stent systems substantially identical to DES Stents being supplied
by Abbott under the supply arrangements, then for each such drug eluting stent
system that Boston Scientific sells or otherwise transfers for value to a third
party (which shall not include samples or drug eluting stent systems provided
at no cost for use in clinical trials), Boston Scientific shall pay to Abbott
an amount equal to the Manufacturing Margin (as defined below).

 

(ii)                                  If
Boston Scientific wishes to substitute the delivery system of a DES Stent,
then, at its option, Boston Scientific shall either (A) deliver the
substitute component to Abbott for inclusion in DES Stents to be supplied by
Abbott to Boston Scientific, or (B) manufacture the DES Stents itself, in
which case Boston Scientific shall, during the term of the applicable supply
arrangement, pay to Abbott the Manufacturing Margin with respect to each such
DES Stent sold or otherwise transferred for value to third parties (which shall
not include samples or DES Stents provided at no cost for use in clinical
trials).

 

(iii)                               At
the request of Boston Scientific, during the term of the supply arrangements,
Abbott will supply to Boston Scientific at cost, for use in DES Stents or any
everolimus-eluting stent system of Boston Scientific, any components used at
any time during the term of the supply arrangements in manufacturing DES Stents
sold by Abbott. If the mere supply of any components pursuant to this Section 5.07(b)(iii) would
result in a breach of any license or other agreement included in the Assets
entered into by Guidant with a third party prior to the Closing, then Abbott
shall have no obligation to supply such components unless Boston Scientific has
entered into a separate written license or other agreement with such third party
authorizing the supply of such components by Abbott to Boston Scientific, and
Abbott shall assist Boston Scientific in obtaining such license or agreement. If
Abbott supplies components to Boston Scientific that, at the time of such
supply, Abbott is not using to make DES Stents, and if such components infringe
the Intellectual Property of a third party, then Boston Scientific will
indemnify Abbott against any damages incurred by Abbott as a result of an
Action by such third party alleging that Abbott’s manufacture, use or sale of
such components supplied to Boston Scientific, or Boston Scientific’s sale or
use of such components, infringes such Intellectual Property. Abbott shall
invoice Boston Scientific with respect to such components upon shipment of such
components, and Boston Scientific shall pay for such components within 45 days
from the date of its receipt of such components.

 

2

 

Boston Scientific shall reimburse Abbott for
any actual costs associated with changeovers from Abbott to Boston Scientific
components included in the DES Stents. Abbott shall invoice Boston Scientific
with respect to costs associated with such changeovers, and Boston Scientific
will make payment on such invoices within 45 days from the date of Abbott’s
invoice. Each invoice delivered by Abbott regarding component or changeover
costs will be subject, at Boston Scientific’s request, to an audit on an annual
basis by a third party reasonably acceptable to the parties. The parties shall
reimburse each other, as applicable, no later than the tenth Business Day
following the completion of such third party audit, for the aggregate amount of
any overpayment or underpayment by Boston Scientific during the applicable year
based on such audit.”

 

(c)                                  Section 5.07(h) of
the Agreement is hereby amended and restated to read as follows:

 

“(h)                           Abbott
shall invoice Boston Scientific with respect to the Abbott Manufacturing Cost
(as defined below) for each DES Stent (including samples of DES Stents)
supplied by Abbott to Boston Scientific upon shipment, and Boston Scientific
shall pay such Abbott Manufacturing Cost to Abbott within 45 days from the date
of receipt by Boston Scientific of such DES Stent. In addition, for each DES
Stent supplied by Abbott to Boston Scientific and sold or otherwise transferred
for value to a third party by Boston Scientific (which shall not include
samples or DES Stents provided at no cost for use in clinical trials), Boston
Scientific shall pay an amount equal to the Manufacturing Margin with respect
to such DES Stent. For purposes of this Agreement, “Abbott Manufacturing
Cost” means, for each DES Stent shipped during the relevant calendar year, (i) $400
in 2006, (ii) $350 in 2007, (iii) $300 in 2008, (iv) $275 in 2009,
and (v) $250 in 2010 and all other calendar years thereafter during the
term of the supply arrangements, in each case as adjusted pursuant to the
provisions of Section 5.07(l).”

 

(d)                                 The
first sentence of Section 5.07(i) is hereby amended and restated to
read as follows:

 

“Boston Scientific will pay directly to a
third party any royalty payments required to be paid to such third party
(pursuant to any license agreements or arrangements with such third party) in
respect of any sales by Boston Scientific or its Affiliates of DES Stents.”

 

(e)                                  Section 5.07(j)
of the Agreement is hereby amended and restated to read as follows:

 

“(j)                               The
“MRG Price” in a particular Territory means the weighted average selling
price of DES Stents or drug eluting stent systems substantially identical to
DES Stents sold or otherwise transferred for value to a third party by Boston
Scientific during the relevant quarter of the term of the applicable supply
arrangement as reflected in reports prepared by Millennium Research Group (or,
if Millennium Research Group does not cover the Rest of the World or Japan, or
is no longer preparing such data for the United States or Europe, by another
independent market research firm reasonably acceptable to the parties); provided
that the MRG Price as it relates to the United States, Europe and Rest of World
will include a discount to such weighted average selling price

 

3

 

of 6% to reflect customary rebates and
discounts for drug eluting stent systems in such Territories, and the MRG Price
as it relates to Japan will include a discount to such weighted average selling
price of 25% to reflect customary rebates, discounts and distribution costs in
Japan, in each case as adjusted pursuant to the provisions of Section 5.07(l).”

 

(f)                                    The
following new Section 5.07(k) is hereby added to the Agreement:

 

“(k)                            Within
45 days following the end of each calendar quarter during the term of the
supply arrangements, Boston Scientific shall pay to Abbott the aggregate
Manufacturing Margin due for such calendar quarter and deliver to Abbott a
written statement showing how such aggregate Manufacturing Margin was
calculated that includes the following information for such calendar quarter in
each Territory (i) the number of DES Stents and/or drug eluting stent
systems substantially identical to DES Stents sold or otherwise transferred for
value to third parties by Boston Scientific (which shall not include samples or
DES Stents provided at no cost for use in clinical trials), and (ii) a
calculation of the per unit Manufacturing Margin payable to Abbott. The per
unit “Manufacturing Margin” shall be equal to 40% of the result obtained
by subtracting from the MRG Price the sum of (A) royalties (calculated
based on the MRG Price) payable to third parties by Boston Scientific with
respect to each DES Stent or drug eluting stent systems substantially identical
to DES Stents sold or otherwise transferred for value to third parties by it
(which shall not include samples or DES Stents provided at no cost for use in
clinical trials), (B) 7% of the MRG Price, representing Boston Scientific’s
variable selling costs for each DES Stent or drug eluting stent systems
substantially identical to DES Stents, and (C) the Abbott Manufacturing
Cost; provided, however, that if during any quarterly period
during the term of the supply arrangement, the MRG Price of the DES Stent
supplied by Abbott in any Territory is less than $400, then the Manufacturing
Margin for such DES Stent in such Territory during the relevant calendar
quarter in which such MRG Price is less than $400 shall instead be equal to 25%
of the Abbott Manufacturing Cost; and, provided, further, that in
no case shall the Manufacturing Margin be less than zero.”

 

(g)                                 The
following new Section 5.07(l) is hereby added to the Agreement:

 

“(l)                               (i) 
On the first Business Day of each of the thirteenth and twenty-first calendar
quarters of the supply arrangements (each, a “True-Up Quarter”), Boston
Scientific will deliver to an independent certified public accountant
reasonably acceptable to the parties (the “True-Up Accountant”) the
following reports covering the first two years (beginning on the first day of
the calendar quarter in which the supply arrangement first becomes effective)
and the next succeeding two years of the term of the supply arrangements,
respectively:

 

(A)                              a
report of Boston Scientific’s average actual cost, calculated on a quarterly
basis, of manufacturing drug eluting stent systems in each Territory pursuant
to Section 5.07(b)(i), and of manufacturing DES Stents in each Territory
pursuant to clause (B) of Section 5.07(b)(ii) (a “Boston
Scientific Cost Report”);

 

4

 

(B)                                a
report of Boston Scientific’s actual weighted average selling price (after
taking into account any rebates and discounts actually granted to customers in
the relevant Territory) (the “Actual Selling Price”), calculated on a
quarterly basis, for DES Stents or drug eluting stent systems substantially
identical to DES Stents sold or otherwise transferred for value to a third
party by Boston Scientific (which shall not include samples or DES Stents
provided at no cost for use in clinical trials) (a “Selling Price Report”);
and

 

(C)                                a
report of average actual royalties paid to third parties by Boston Scientific
pursuant to Section 5.07(i) (“Actual Royalties”), calculated
on a quarterly basis, with respect to DES Stents or drug eluting stent systems
substantially identical to DES Stents sold or otherwise transferred for value
to a third party by Boston Scientific (which shall not include samples or DES
Stents provided at no cost for use in clinical trials) (a “Royalty Report”).

 

On the first Business Day of the third
calendar quarter following any termination of a supply arrangement (a “Final
True-Up Quarter”), Boston Scientific will deliver to the True-Up Accountant
a Boston Scientific Cost Report, a Selling Price Report and a Royalty Report
for any period remaining in the term of such supply arrangement following the
fourth year of such supply arrangement. Each Boston Scientific Cost Report,
Selling Price Report and Royalty Report delivered pursuant to this Section 5.07(l)(i) will
be subject, at Abbott’s request, to an audit by a third party reasonably
acceptable to the parties.

 

(ii)                                  On
the first Business Day of the first True-Up Quarter, Abbott will deliver to the
True-Up Accountant a report of its average actual cost, calculated on a
quarterly basis, of manufacturing DES Stents in each Territory (an “Abbott
Cost Report”) for the first two years (beginning on the first day of the
calendar quarter in which the supply arrangement first becomes effective) of
the term of the supply arrangements. On the first Business Day of the second
True-Up Quarter, Abbott will deliver to the True-Up Accountant an Abbott Cost
Report for the next succeeding two years of the term of the supply arrangements.
On the first Business Day of a Final True-Up Quarter, Abbott will deliver to
the True-Up Accountant an Abbott Cost Report for any period remaining in the
term of such supply arrangement following the fourth year of such supply
arrangement. Each Abbott Cost Report delivered pursuant to this Section 5.07(l)(ii) will
be subject, at Boston Scientific’s request, to an audit by a third party
reasonably acceptable to the parties.

 

(iii)                               If (A) Boston
Scientific’s or Abbott’s actual manufacturing costs during the period covered
by a Boston Scientific Cost Report or Abbott Cost Report, as applicable, are
greater or less than the Abbott Manufacturing Cost during such period, (B) Boston
Scientific’s Actual Selling Price during the period covered by a Selling Price
Report is greater or less than the MRG Price during such period, or (C) the
Actual Royalties paid by Boston Scientific during the period covered by a
Royalty Report are greater or less than the amount of royalties calculated
based on MRG Price for purposes of calculating the Manufacturing Margin during
such period, then the True-Up Accountant shall recalculate the amounts that
would have been payable by Boston

 

5

 

Scientific to Abbott during such period
pursuant to Sections 5.07(b)(i) and 5.07(b)(ii)(B) (assuming for
purposes of this clause (iii) that the reference to “Abbott Manufacturing
Cost” in clause (C) of the definition of Manufacturing Margin is a
reference to Boston Scientific’s actual cost of manufacturing drug eluting
stent systems) and Section 5.07(h) (assuming for purposes of this
clause (iii) that the reference to “Abbott Manufacturing Cost” in clause (C) of
the definition of Manufacturing Margin is a reference to Abbott’s actual cost
of manufacturing DES Stents) using the actual manufacturing costs, Actual
Selling Prices and Actual Royalties, and the parties shall reimburse each other,
as applicable, for the aggregate amount of any overpayment or underpayment by
Boston Scientific during such period based on such recalculated amount. Any
such payment will be made no later than the later of (x) the twentieth Business
Day of such True-Up Quarter or the Final True-Up Quarter, as applicable, and
(y) the tenth Business Day following the completion by a third party of its
audit of any Boston Scientific Cost Report, Abbott Cost Report, Selling Price
Report or Royalty Report as applicable.

 

(iv)                              Boston
Scientific and Abbott shall cause the True-Up Accountant and each third party
auditor to treat confidentially each Boston Scientific Cost Report, Abbott Cost
Report, Selling Price Report and Royalty Report.”

 

(h)                                 The
second sentence of Section 5.08(d) of the Agreement is hereby amended
and restated to read as follows:

 

“From and after the Closing, the parties will
discuss in good faith what action, if any, should be taken if either party
believes that a third party is infringing any DES Intellectual Property.”

 

(i)                                     The
following new Section 6.06 is hereby added to the Agreement:

 

“SECTION 6.06.
Agreement to Vote; Proxies. As of the Closing, Abbott shall grant to
Boston Scientific or any of its designees an irrevocable proxy and shall
appoint Boston Scientific or any of its designees as attorney-in-fact for
Abbott and each of its Affiliates that beneficially owns Shares received
pursuant to Sections 6.01 and 6.05, for so long as Abbott and such Affiliates
beneficially own such Shares, with respect to any matter to be voted on by
stockholders of Boston Scientific. All such Shares shall be voted
proportionately with the vote cast by all other stockholders of Boston
Scientific entitled to vote and voting on such matter. Upon the sale, transfer,
assignment or other disposition of such Shares by Abbott or any Affiliate to an
unaffiliated third party, the proxy granted pursuant to this Section 6.06
with respect to such Shares so transferred, assigned or disposed shall be
automatically revoked, and the appointment pursuant to this Section 6.06
as attorney-in-fact with respect to such Shares shall be automatically
terminated.”

 

(j)                                     The
following new Section 6.07 is hereby added to the Agreement:

 

“SECTION 6.07.
Full Sale and Divestiture of Shares. Subject to Section 6.02(a),
Abbott agrees to sell, transfer or otherwise dispose of all Shares received
pursuant to Sections 6.01 and 6.05 hereof to an unaffiliated third party no
later than thirty (30)

 

6

 

months following the Closing.”

 

(k)                                  Clause
(c) of Section 12.06 of the Agreement is hereby amended and restated
to read as follows:

 

“(c) Abbott may, without the consent of
Boston Scientific, assign its rights and obligations, in whole or in part,
under this Agreement to any designee of Abbott (in the event Abbott divests any
of the Assets that would otherwise be acquired by Abbott pursuant hereto due to
applicable antitrust laws and regulations) or to any acquiror of all or
substantially all of Abbott’s vascular intervention business.”

 

SECTION 2. Public Announcement. The
provisions contained in Section 12.03 of the Agreement are incorporated by
reference in this Amendment 3 as though they were expressly set forth herein.

 

SECTION 3. Representations and
Warranties. (a) Boston Scientific represents and warrants to Abbott as
follows:  Boston Scientific is a
corporation duly incorporated, validly existing and in good standing under the
Laws of the State of Delaware and has all necessary corporate power and
authority to enter into, execute and deliver this Amendment 3, to carry out its
obligations hereunder and to consummate the transactions contemplated hereby. The
execution and delivery of this Amendment 3 by Boston Scientific, the
performance by Boston Scientific of its obligations hereunder and the
consummation by Boston Scientific of the transactions contemplated hereby have
been duly authorized by all requisite corporate action on the part of
Boston Scientific. This Amendment 3 has been duly executed and delivered by Boston
Scientific, and, assuming due authorization, execution and delivery by Abbott,
this Amendment 3 is a legal, valid and binding obligation of Boston Scientific,
enforceable against it in accordance with its terms.

 

(b)                                 Abbott
represents and warrants to Boston Scientific as follows:  Abbott
is a corporation duly incorporated, validly existing and in good standing under
the laws of the State of Illinois and has all necessary corporate power and
authority to enter into, execute and deliver this Amendment 3, to carry out its
obligations hereunder and to consummate the transactions contemplated hereby. The
execution and delivery of this Amendment 3 by Abbott, the performance by Abbott of its obligations hereunder and the
consummation by Abbott
of the transactions contemplated hereby have been duly authorized by all
requisite corporate action on the part of Abbott. This Amendment 3 has been duly executed and
delivered by Abbott,
and, assuming due authorization, execution and delivery by Boston Scientific,
this Amendment 3 is a legal, valid and binding obligation of Abbott enforceable
against it in accordance with its terms.

 

SECTION 4. Ratification of Agreement.
Except as expressly provided in this Amendment 3, all of the terms, covenants,
and other provisions of the Agreement are hereby ratified and confirmed and
shall continue to be in full force and effect in accordance with their
respective terms. From and after the date hereof, all references to the
Agreement shall refer to the Agreement as amended by this Amendment 3. Capitalized
terms used but not defined in this Amendment 3 shall have the meanings assigned
to them in the Agreement.

 

SECTION 5. Governing Law. This
Amendment 3 shall be governed by, and construed in

 

7

 

accordance with, the laws of the State of New
York. All Actions arising out of or relating to this Amendment 3 shall be heard
and determined exclusively in any New York federal court sitting in the Borough
of Manhattan of The City of New York.

 

SECTION 6. Counterparts. This
Amendment 3 may be executed and delivered (including by facsimile
transmission) in one or more counterparts, and by the different parties hereto
in separate counterparts, each of which when executed shall be deemed to be an
original, but all of which taken together shall constitute one and the same
agreement.

 

*   *  
*   *

 

8

 

IN WITNESS WHEREOF, Boston Scientific and Abbott have
caused this Amendment 3 to be executed as of the date first written above by
their respective officers thereunto duly authorized.

 

	
   

  	
  BOSTON SCIENTIFIC CORPORATION

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  /s/ Lawrence C. Best

  	
   

  
	
   

  	
   

  	
  Name:

  	
  Lawrence C. Best

  
	
   

  	
   

  	
  Title:

  	
  Executive Vice President, Chief

  
	
   

  	
   

  	
   

  	
  Financial Officer

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  ABBOTT LABORATORIES

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
  Name:

  	
  Richard A. Gonzalez

  
	
   

  	
   

  	
  Title:

  	
  President and Chief Operating

  
	
   

  	
   

  	
   

  	
  Officer, Medical Products

  
	
   

  	
   

  	
   

  	
  Group

  

 

 

IN WITNESS WHEREOF, Boston Scientific and Abbott have
caused this Amendment 3 to be executed as of the date first written above by
their respective officers thereunto duly authorized.

 

	
   

  	
  BOSTON SCIENTIFIC CORPORATION

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
   

  	
   

  
	
   

  	
   

  	
  Name:

  	
  Lawrence C. Best

  
	
   

  	
   

  	
  Title:

  	
  Executive Vice President, Chief

  
	
   

  	
   

  	
   

  	
  Financial Officer

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  ABBOTT LABORATORIES

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  /s/ Richard A. Gonzalez

  	
   

  
	
   

  	
   

  	
  Name:

  	
  Richard A. Gonzalez

  
	
   

  	
   

  	
  Title:

  	
  President and Chief Operating

  
	
   

  	
   

  	
   

  	
  Officer, Medical Products

  
	
   

  	
   

  	
   

  	
  Group

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}]]